Scientific Research
This page is in a'blog' format with the latest scientific PSC research identified by Google Scholar, Readbyqmx.com and other sources added regularly.

Abstract

Background & Aims
The association between primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD) is well recognised. However, the relationship between IBD and recurrent PSC (rPSC) is less well understood. We assessed the prevalence of rPSC and analysed the factors associated with rPSC post-liver transplantation and its influence on graft and patient survival.
Methods
This is a UK multicentre observational cohort study across six of the seven national liver transplant units. All patients undergoing a first liver transplant for PSC between January 1 1990 and December 31 2010 were included. Prospectively collected liver transplant data ... Please click here to read the full text of this article.

Reyna Ravikumar et al
Journal of Hepatology, November 2015, 63, 5, pp 1139-1146

John M Fell, Rafeeq Muhammed, Chris Spray, Kay Crook, Richard K Russell, BSPGHAN IBD working group

Abstract
​Ulcerative colitis (UC) in children is increasing. The range of treatments available has also increased too but around 1 in 4 children still require surgery to control their disease. An up-to-date understanding of treatments is essential for all clinicians involved in the care of UC patients to ensure appropriate and timely treatment while minimising the risk of complications and side effects.

Please click here to read the full article

Arch Dis Child doi:10.1136/archdischild-2014-307218

David Al Dulaimi
Department of Gastroenterology, Alexandra Hospital, Redditch, UK 

This link will take you to a number of synopsis of recent papers considering the advances of knowledge in inflammatory bowel disease.

​Papers were prepared by:
Drs Luke Materacki and Ishfaq Ahmad, Alexandra Hospital, UK

Gastroenterol Hepatol Bed Bench 2014;8(4):313-315 

INTRODUCTION

Patients with ulcerative colitis or Crohn’s colitis have an increased risk of colorectal cancer (CRC). Most cases are believed to arise from dysplasia, and surveillance colonos- copy therefore is recommended to detect dysplasia. Detec- tion of dysplasia traditionally has relied on both examination of the mucosa with targeted biopsies of visible lesions and extensive random biopsies to identify invisible dysplasia ... Please click here to read the full text version of this consensus statement.

Gastrointestinal Endoscopy, 2015, 81 (3)
Copyright a 2015 by the American Society for Gastrointestinal Endoscopy and American Gastroenterological Association
http://dx.doi.org/10.1016/j.gie.2014.12.009 ​

Outcome of patients with primary sclerosing cholangitis and ulcerative colitis undergoing colectomy

Sombat Treeprasertsuk, Einar Björnsson, Emmanouil Sinakos, Emma Weeding, Keith D Lindor

AIM: 
To study the outcomes of primary sclerosing cholangitis (PSC) patients with ulcerative colitis (UC) undergoing colectomy.

METHODS: 
We identified 193 patients with PSC and UC undergoing colectomy at the Mayo Clinic (Rochester, MN, United States), between January 1, 1995 and December 31, 2008 using a computerized record system. Eighty-nine patients were excluded due to unclear diagnosis, liver transplantation prior to colectomy, age less than 18 years, inadequate follow-up data or known cases of cholangiocarcinoma. We retrospectively reviewed data from patient medical records. Clinical information, date of colectomy, preoperative and follow-up liver tests and pathological findings of the colon were reviewed. The Mayo risk score at baseline was calculated to obtain survival estimates for up to 4 years of follow-up.  ... Please click here to read the remainder of the abstract

World Journal of Gastrointestinal Pharmacology and Therapeutics 2013 August 6, 4 (3): 61-8

Malignancy in primary sclerosing cholangitis: Bile duct, liver, and colon

Roger W. Chapman. Clinical Liver Disease Special Issue: Autoimmune Liver Disease, Part 4, 2014, Volume 3, Issue 4,  pages 83–85,

Abstract

As discussed in companion articles in CLD, the clinical course of large duct primary sclerosing cholangitis (PSC) is highly variable and unpredictable.[1, 2] Although the median survival from presentation to death or liver transplantation in symptomatic patients is approximately 10-12 years, 75% of asymptomatic patients will survive 15 years or more. A recent Dutch study has shown an overall median survival of 22 years in PSC patients.[3] . . . Please click here for the full article

An interview with the author and a video presentation of this article is available by clicking here.

Update on inflammatory bowel disease in patients with primary sclerosing cholangitis

Christos Tsaitas, Anysia Semertzidou and Emmanouil Sinakos. World J Hepatol. 2014 April 27; 6(4): 1780-187. Published online 2014 April 27. doi: 10.4254/wjh.v6.i4.178.

Abstract

Patients with primary sclerosing cholangitis (PSC) complicated by inflammatory bowel disease (IBD) represent a distinct subset of patients with unique characteristics, which have serious clinical implications. The aim of this literature review was to shed light to the obscure clinical and molecular aspects of the two diseases combined utilizing current data available and putting issues of diagnosis and treatment into perspective. The prevalence of IBD, mainly ulcerative colitis in PSC patients is estimated to be 21%-80%, dependent on screening programs and nationality . . .  Please click here to read further

Mitsuro Chiba, Hidehiko Tsuda, Satoko Tsuda, Masafumi Komatsu, Yasuo Horie, Hirohide Ohnishi

Abstract

Primary sclerosing cholangitis (PSC) is commonly associated with ulcerative colitis (UC). PSC progresses independently of UC ultimately resulting in liver failure. There is no established medi- cal treatment to improve the natural course of PSC. Normalization of serum alkaline phosphatase (ALP) in early stage might delay the progress of PSC. A 20-year-old female, had a sudden attack of right hypochondralgia with high fever and abnormal liver function tests without elevation of bili- rubin: ALP 478 IU/L, aspartate aminotransferase 360 IU/L, alanine aminotransferase 174 IU/L. Abnormal liver function tests returned to normal after the attacks. Morphological examinations initially indicated then confirmed a diagnosis of PSC. One month after displaying PSC symptoms administration of ursodeoxycholic acid was initiated. Similar attacks of cholangitis were repeated several times over the following two years. Even in the absence of these attacks, she always suf- fered postprandial hypochondralgia ... Full article available by clicking on the title

Copyright © 2014 by authors and Scientific Research Publishing Inc
This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/